Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Diabetologia. 2013 Aug 10;56(11):10.1007/s00125-013-3009-7. doi: 10.1007/s00125-013-3009-7

Fig. 1.

Fig. 1

Effect of B2AR agonist systemic administration on glucose metabolism during hypoglycaemic clamp. Plasma glucose concentration (a), GIR (b), glucose production (c) and glucose uptake (d) for rats receiving injection of the vehicle (control; n=5) and the B2AR agonist formoterol (n=5) during the hyperinsulinaemic–hypoglycaemic glucose clamp. The arrow indicates the time at which the B2AR agonist was delivered. Circles, B2AR agonist; squares, controls. Results are presented as mean±SEM. *p<0.05 and ***p<0.001 vs control